Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 3:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 842 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Muscle Atrophy Clear all
Completed Phase 1 Interventional Results available

Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients

NCT02530905
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
SRP-4045, Placebo
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
7 Years to 21 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 4, 2026, 3:27 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

NS-050/NCNP-03 in Boys With DMD (Meteor50)

NCT06053814
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
NS-050/NCNP-03, Placebo
Drug
Lead sponsor
NS Pharma, Inc.
Industry
Eligibility
4 Years to 15 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 4, 2026, 3:27 PM EDT
Active, not recruiting Not applicable Interventional

The Role of Blood Flow Restriction Therapy in Postoperative Elderly Patients With Hip Fracture

NCT04809714
View directory record Official record
Conditions
Hip Fractures, Muscle Atrophy
Interventions
Blood Flow Restriction with Delfi Tourniquet System Cuff, Routine Post-operative Physical Therapy
Device · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 4, 2026, 3:27 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants

NCT02908685
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Placebo, Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 25 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Palo Alto, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 4, 2026, 3:27 PM EDT
Recruiting No phase listed Observational

DMCRN-02-001: Assessing Pediatric Endpoints in DM1

NCT05224778
View directory record Official record
Conditions
Congenital Myotonic Dystrophy, CDM
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Up to 59 Months
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Fairway, Kansas • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 4, 2026, 3:27 PM EDT
Withdrawn No phase listed Observational

Multi-disease Carrier Screening Test Validation

NCT01663584
View directory record Official record
Conditions
Spinal Muscular Atrophy (SMA), Carrier Screening, Genetic Testing
Interventions
Blood draw
Procedure
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
San Carlos, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Sep 4, 2026, 3:27 PM EDT
Active, not recruiting Phase 2 Interventional

Stromal Vascular Fraction Cell Therapy to Improve the Repair of Rotator Cuff Tears

NCT03332238
View directory record Official record
Conditions
Rotator Cuff Tear, Muscle Atrophy, Tendon Tear
Interventions
Autologous Stomal Vascular Fraction Material, Ringer's solution
Device
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 4, 2026, 3:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of ALS Reversals 2: Genetic Analyses

NCT03464903
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Progressive Muscular Atrophy
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Sep 4, 2026, 3:27 PM EDT
Active, not recruiting Phase 4 Interventional

Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)

NCT04687020
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Viltolarsen
Drug
Lead sponsor
NS Pharma, Inc.
Industry
Eligibility
Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
4
States / cities
Sacramento, California • Chicago, Illinois • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Sep 4, 2026, 3:27 PM EDT
Completed Phase 2 Interventional Results available

A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study

NCT02468674
View directory record Official record
Conditions
Sarcopenia
Interventions
bimagrumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
70 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Miami Lakes, Florida • Gainesville, Georgia • Spartanburg, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 4, 2026, 3:27 PM EDT
Not listed No phase listed Observational

The QUALITY Vets Project: Muscle Quality and Kidney Disease

NCT03160326
View directory record Official record
Conditions
Chronic Kidney Disease, Sarcopenia
Interventions
Not listed
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 84 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
San Francisco, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Sep 4, 2026, 3:27 PM EDT
Terminated Phase 2 Interventional Results available

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

NCT00918385
View directory record Official record
Conditions
Prostate Cancer
Interventions
Nilutamide, Dasatinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Durham, North Carolina • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Sep 4, 2026, 3:27 PM EDT
No Longer Available No phase listed Expanded access

Extension Study of Drisapersen in DMD Subjects

NCT02636686
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Drisapersen
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
5 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 4, 2026, 3:27 PM EDT
Completed Phase 2 Interventional Results available

Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy

NCT02913482
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Month to 7 Months
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Palo Alto, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 4, 2026, 3:27 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Metformin and Muscle Recovery

NCT06185179
View directory record Official record
Conditions
Muscle Atrophy or Weakness
Interventions
Metformin, Placebo
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
60 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Sep 4, 2026, 3:27 PM EDT
Recruiting No phase listed Observational

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

NCT07702461
View directory record Official record
Conditions
Obesity & Overweight, Diabetes (DM)
Interventions
Glucagon-Like Peptide-1 Agonist (GLP-1)
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 4, 2026, 3:27 PM EDT
Active, not recruiting Phase 4 Interventional

Muscle Impact of Treating Osteoporosis

NCT05666310
View directory record Official record
Conditions
Sarcopenia, Osteoporosis
Interventions
Denosumab, Zoledronic Acid, Denosumab Placebo, Zoledronic Acid Placebo
Drug · Other
Lead sponsor
Nami Safai Haeri
Other
Eligibility
65 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 4, 2026, 3:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the Reproducibility of Jumping Mechanography

NCT01164670
View directory record Official record
Conditions
Sarcopenia
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
70 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Sep 4, 2026, 3:27 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Prospective Evaluation of Infants With Spinal Muscular Atrophy:

NCT02831296
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 4, 2026, 3:27 PM EDT
No Longer Available No phase listed Expanded access

HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy.

NCT05154851
View directory record Official record
Conditions
Congenital Muscular Dystrophy Due to Lamin A/C Mutation
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
Not listed
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 4, 2026, 3:27 PM EDT
Recruiting No phase listed Observational

Gait and Bone Health in SMA

NCT07400198
View directory record Official record
Conditions
Spinal Muscular Atrophy Type 3, Ambulatory Spinal Muscular Atrophy
Interventions
Not listed
Lead sponsor
Jacqueline Montes
Other
Eligibility
8 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 4, 2026, 3:27 PM EDT
Completed Phase 3 Interventional

A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)

NCT04729907
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Nusinersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
2 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Sacramento, California • Aurora, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 4, 2026, 3:27 PM EDT
Terminated Phase 3 Interventional

A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.

NCT05689164
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
fordadistrogene movaparvovec
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Durham, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 4, 2026, 3:27 PM EDT
Active, not recruiting Not applicable Interventional

Progressive Rehabilitation Therapy in Patients With Advanced Lung Disease

NCT03562728
View directory record Official record
Conditions
Advanced Lung Disease, Lung Transplant, Extracorporeal Membrane Oxygenation
Interventions
MRP and NMES(neuromuscular electric stimulation), Standard of Care
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 4, 2026, 3:27 PM EDT